Merge, LLC

Merge Clinical Study Communications developed a highly effective tool for reporting pre-identified patients – in under 6 weeks, in 38 countries, with no technical issues. Learn more.

Home - Merge Clinical Study Communications Pardon us as we update, redesign, and improve our website’s efficiency with an advanced new formula.

Clinical trial patients being the ones who endure the burden of their disease & encounter trial barriers is “a national problem [that] requires a local solution,” says Mimi Fenton, CEO of Cedar Health Research. Fenton found that when gaining community trust was prioritized, underrepresented groups were more eager to engage in trials.

In an Ecosystem of Trust, Trial Enthusiasm can ‘Spread Like Wildfire’ Discover the Latest News in Clinical Research, Clinical Trials, Medical Informatics, & More. Clinical Research News Online Provides Daily Insights, News, & Analysis for the Clinical Research Industry.

Once upon a time, DCTs promised faster timelines, wider access & lowered costs. However, a recent study shows DCTs haven’t delivered results the way many anticipated, which has caused industry interest to decline. In 2022, the use of DCTs nearly returned to pre-pandemic levels. Read on here:

Decentralized studies yet to yield the expected benefits, according to study Decentralized trials (DCTs) may not accelerate drug research and reduce costs to the extent previously thought, according to a new study.

Keep your study top-of-mind with all study stakeholders. Learn more about Brandbuilder – from Merge Clinical Study Communications.

Home - Merge Clinical Study Communications Pardon us as we update, redesign, and improve our website’s efficiency with an advanced new formula.

This , we celebrate the clinical trial volunteers who play a vital role in advancing medical research and bringing new treatments to life. Thank you for being the heart of progress! 🧪🫶🏼🔎

The FDA issued a guide to enhance how clinical trials enroll underrepresented patients. Now, broadening I/E criteria is encouraged to embody a more inclusive, real-world sample of the population. Underrepresentation must be challenged to produce viable evidence & real‑world relevance going forward. Read on:

FDA Issues Final Guidance On Clinical Trial Participation: What You Need To Do Now On December 15, 2025, the FDA finalized its guidance Enhancing Participation in Clinical Trials, formally updating expectations for enrollment and trial design. Heres what you can do now.

Merge Clinical Study Communications excels at media strategy, planning and placement – in traditional media – and in online, mobile and social media – nationally, and globally.

Home - Merge Clinical Study Communications Pardon us as we update, redesign, and improve our website’s efficiency with an advanced new formula.

Merge Clinical Study Communications is known for creating messages that stand apart from the ordinary – in every therapeutic area.

mergellc.com Clinical Study Communications Pardon us as we update, redesign, and improve our website’s efficiency with an advanced new formula.

Did you know that nearly 95% of rare diseases have 0 approved treatment options? This means that clinical trials are usually the only treatment option available for rare disease patients. Ruthie Davi, a VP at Medidata , campaigns for the increased use of technology in rare disease trials to improve timelines, experiences, and outcomes. Read more:

Rare Disease Day: Revolutionising clinical trial enrolment and retention with technology Ruthie Davi, vice president of statistics and regulatory innovation at Medidata, highlights the value of technology in rare disease trials.

This , we recognize the power of clinical trials in shaping the future of medicine. Every trial brings us closer to safer, more effective treatments for patients everywhere.💙🍎🌍

It’s ! To all the physicians and clinical researchers, thank you for your long hours, your expertise, and the difference you make in so many lives. 🩺 💙🥼